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To report on local control and survival after breast-conserving therapy (BCT) 
including three-dimensional conformal simultaneous integrated boost irradiation 
(3D-CRT-SIB) and on the influence of age on outcome.
Patient and Methods
For this study, 752 consecutive female breast cancer patients (stages I-III), 
treated with 3D-CRT-SIB at the University Medical Center Groningen from 2005 
to 2008, were retrospectively identified. Median age was 58.4 (range 26-84) 
years. The SIB fractionation used was: 28 x 1.8 Gy (whole breast) and 28 x 2.3 
Gy or 2.4 Gy (tumour bed). Next to outcome, we estimated the effect of age on 
the recurrence-free period (RFP) by multivariate Cox regression survival analysis.
Results
Median follow-up was 41 (range 3-65) months. Local control was 99.6% at 3 
years (6 ipsilateral recurrences). The 3-year locoregional control, RFP and overall 
survival (OS) rates were 99.2%, 95.5%, and 97.1%, respectively. In multivariate 
analysis, tumours > 2 cm (hazard ratio (HR) 3.11, 95% confidence interval (CI) 
1.57-6.17) and triple negativity (HR 3.03, 95% CI 1.37-6.67) and not age were 
associated with impaired RFP.
Conclusions
At 3 years, the 3D-CRT-SIB technique in BCT results in excellent local control and 
OS. Age was not a risk factor for any recurrence.
Introduction
Radiotherapy is considered an integral part of breast-conserving therapy (BCT) 
in patients with invasive breast cancer, since both local control (LC) and overall 
survival (OS) improved significantly by combining breast-conserving surgery with 
RT 1,2. Currently, BCT is considered standard of care for patients with stages I-II 
disease 3.
 Conventional breast radiotherapy is delivered to the whole breast and is often 
followed by an additional boost dose to the tumour bed 4. Breast irradiation with a 
boost to the tumour bed provides significantly higher LC rates than whole breast 
irradiation alone, 93.8% vs. 89.8% at 10 years, respectively 5. Since 2005, at 
our department, radiotherapy after lumpectomy is administered with a threedi-
mensional conformal-technique with a hypofractionated simultaneous integrated 
boost (3D-CRT-SIB). With the 3D-CRT-SIB technique 6, whole breast and boost ir-
radiation are combined in one treatment plan and are given simultaneously. With 
the SIB, the mean volume receiving P107% of the breast dose was reduced by 
20%, the mean volume outside the boost planning target volume receiving P95% 
of the boost dose was reduced by 54%, and the mean heart and lung dose were 
reduced by 10% compared to the sequential boost technique 6. Due to the higher 
dose per fraction to the tumour bed, the overall treatment time can be reduced 
with 2 weeks, which adds substantially to patient convenience. In addition, we 
showed that the 3D-CRT-SIB was superior to the sequential boost-technique with 
respect to unintended excessive dose to the area outside the boost 6. Despite the 
somewhat higher dose per fraction to the boost area, acute toxicity after 3D-CRT-
SIB was mild and remained within acceptable limits 6.
 Studies reporting on BCT show that treatment outcome in terms of LC is signifi-
cantly worse in younger patients compared to older patients 7-10. In the European 
Organisation for Research and Treatment of Cancer (EORTC) study 22881-10882, 
the absolute benefit of a boost in terms of local control was most pronounced in 
young patients 5. Differences exist between the aforementioned 3D-CRT-SIB tech-
nique, and the techniques that were used in the EORTC study 22881-10882. In 
contrast to the EORTC study, all patients treated with 3D-CRT-SIB were planned 
using a computer tomography (CT) scan which may improve reconstruction of 
the exact location and volume of the boost area. Furthermore, CT-based planning 
provides more accurate information on the dose distribution and offers the oppor-
tunity to optimise dose homogeneity and dose conformity. As the local recurrence 
rate is expected to be highest in younger patients, the question arises whether 
such a difference would also be present after breast irradiation with the 3D-CRT-
SIB technique.
 Therefore, the purpose of this paper was to evaluate the clinical outcome of 
a consecutive series of patients with invasive breast cancer treated with the 































Age at diagnosis (y) 
 ≤ 50 204 (27.1)
 > 50 548 (72.9)
BCRA 1 or 2 mutation 
 Absent 22 (2.9)
 Present 12 (1.6)
 Unknown 718 (95.5)
Pathologic T-stage 
 T1 561 (74.6)
 T ≥ 2 191 (25.4)
Pathologic N-stage 
 N0 522 (69.4)
 N1 190 (25.3)
 N2+ 37 (4.9)
 Nx 3 (0.4)
Histology 
 Invasive ductal 658 (87.4)
 Invasive lobular 66 (8.8)
 Other 28 (3.7)
Multifocality 
 No 728 (96.8)
 Yes 24 (3.2)
Status resection margins 
 Negative 635 (84.4)
 (Focally) positive 109 (14.5)
 Missing 8 (1.1)
Differentiation grade 
 I/II 550 (73.1)
 III 193 (25.7)
 Missing 9 (1.2)
Lymphovascular invasion 
 Absent 696 (92.6)
 Present 56 (7.4)
Extensive DCIS 
 Absent 684 (91.0)
 Present 68 (9.0)
Characteristic n (%)
Table 1. Patient and tumour characteristics 
(n = 752)
Extra nodal growth 
 Absent 694 (92.3)
 Present 58 (7.7)
Oestrogen receptor (ER) 
 Positive 595 (79.1)
 Negative 126 (16.8)
 Missing 31 (4.1)
Progesterone receptor (PR) 
 Positive 514 (68.4)
 Negative 205 (27.3)
 Missing 33 (4.4)
HER2 receptor 
 Positive 69 (9.2)
 Negative 626 (83.2)
 Missing 57 (7.6)
Triple negative 1 
 No 659 (87.6)
 Yes 93 (12.4)
Adjuvant chemotherapy 
 No 486 (64.6)
 Yes 266 (35.4)
Adjuvant hormonal therapy 
 No 461 (61.3)
 Yes 291 (38.7)
Adjuvant trastuzumab 
 No 715 (95.1)
 Yes 37 (4.9)
Regional radiotherapy 
 No 707 (94.0)
 Yes 45 (6.0)
Boost dosage 
 Low (64.4 Gy) 573 (76.2)
 High (67.2 Gy) 179 (23.8)
Characteristic n (%)
Table 1. (continued)
Abbreviations: DCIS = ductal carcinoma in 
situ; HER2 = human epidermal growth factor 
receptor 2.
1 ER negative, PR negative, and HER2 negative.
Patients and methods
Study population
The study population was composed of 752 consecutive female invasive breast 
cancer patients (Stages I-III) treated with breast-conserving surgery. All patients 
were treated with postoperative radiotherapy using 3D-CRT-SIB at the depart-
ment of Radiation Oncology of the University Medical Center Groningen between 
January 2005 and January 2008. Excluded were male patients, patients with a 
history of invasive cancer (except non-melanoma skin cancer or carcinoma in 
situ of the cervix), previous irradiation to the thorax, patients diagnosed with 
synchronous contralateral breast cancer (i.e., breast cancer diagnosed in both 
breasts simultaneously or within a 3-month period of diagnosis of the first tu-
mour), and patients treated with neo-adjuvant chemotherapy. 
 The median age at diagnosis was 58.4 (range 26-84) years. There were 204 
patients (27.1%) aged 50 years or younger at time of diagnosis. Patient, tumour 
and treatment characteristics are listed in Table 1.
Data collection
Patient, tumour and treatment-related characteristics as well as follow-up data 
were collected retrospectively from the medical files. The following data were 
collected: age at diagnosis, information regarding primary surgery, adjuvant che-
motherapy and hormonal treatment, regional radiotherapy, tumour recurrence, 
distant metastases, and death. Data regarding tumour size, lymph node status, 
number of metastatic lymph nodes, positive apical lymph nodes, histologic diag-
nosis and grade, presence of lymphovascular invasion and extensive ductal car-
cinoma in situ (DCIS), multifocality, resection margin status, and receptor status 
were obtained directly from the pathology report. Patients were staged according 
to the TNM classification system (IUCC 2002) 3.
 In 52 cases with missing data (mainly follow-up), the general practitioner was 
contacted for additional information. In 42 cases (80.8%), the additional fol-
low-up data were provided. Data were entered in a database and maintained by 
a data manager. Data collection of the present study was conducted under com-
pliance of the hospital institutional review board regulations.
Toxicity	scoring
During routine follow-up at our department, the physician-rated, late toxicity was 
prospectively assessed according to the Common Terminology Criteria of Adverse 
Events version 3.0 (CTCAE v3.0) 11. Routine out-patient visits were made yearly, 
from the first year to 5 years after radiotherapy. 
Definitions
Because it was not possible to differentiate between a true LR and new primary 
tumours in the ipsilateral breast, LR was defined as any recurrence, either inva-
sive or in situ carcinoma, in the ipsilateral breast or overlying skin. Regional re-






























or internal mammary lymph nodes without clinical or radiologic evidence of dis-
tant metastases. Locoregional recurrence (LRR) was defined as either LR or RR. 
LRR was considered an event if this was not preceded by distant metastases (i.e., 
first event). In case of simultaneous LRR and distant metastases, the locoregional 
event was considered the first event in the analyses.
 Distant metastases were defined as all cancers, spread from the primary tu-
mour, occurring at sites other than local or regional sites. Death of disease was 
defined death preceded by LRR or distant metastases. Overall survival considered 
deaths of any cause.
 Endpoints were calculated as the interval between pathologic diagnosis of pri-
mary breast cancer and the event of interest or date of last follow-up. As few LRR 
events were expected, an additional endpoint was defined to investigate disease 
progression, including the recurrence-free period (RFP) defined as the time of 
date of diagnosis until any recurrence (LRR or distant metastases). RFP was pre-
sented as 1 minus the cumulative incidence of any recurrence.
 Multifocality was considered positive as two or more foci of the invasive com-
ponent were present in the pathologic specimen. Resection margins were consid-
ered microscopically involved in case of a positive resection margin or a margin of 
less than 1 mm. Otherwise, the margin was considered to be tumour free. DCIS 
was classified as extensive if 10 or more ducts were involved. The apical lymph 
node was defined as the most cranial positioned lymph node in the axillary dis-
section specimen as marked by the surgeon.
Radiotherapy
Patients were treated with 3D-CRT-SIB as part of BCT. This technique and choice 
of fractionation has been described in more detail by van der Laan et al. 6. Briefly, 
with the SIB technique, breast and boost beams are combined in one integrat-
ed treatment plan, i.e., patients are treated with the same plan each fraction 
throughout the entire course of treatment. Fractionation schemes used were 28 
daily fractions of 1.8 Gray (Gy) to the whole breast PTV and 2.3 Gy (76.2%) or 
2.4 Gy (23.8%), in case of involved or focally positive resection margins, to the 
boost planning target volume planning target volume, adding up to a total dose 
of 64.4 Gy or 67.2 Gy. These fractionation schemes are biologically equivalent 
to the sequential boost-technique comprising 25 fractions of 2 Gy to the whole 
breast PTV followed by a boost irradiation in 8 or 10 fractions, using an α/β ratio 
of 10 Gy for tumour response, based on the linear-quadratic cell survival model 12.
 The breast clinical target volume (CTV) included the glandular breast tissue of 
the ipsilateral breast, excluding the major pectoral muscle, the ribs and the skin. 
The tumour bed CTV was delineated guided by the presence of the surgical clips, 
hematoma, seroma and/or other surgery-induced changes. Breast and boost 
CTVs were expanded with a margin of 5 mm to generate the breast and boost 
PTVs. For the breast PTV, a margin of 10 mm was used in the cranial and caudal 
directions. The 3D-CRT-SIB treatment plans consisted of tangential breast beams 
with multileaf collimator (MLC) shielding conformal to the breast PTV. In general, 
one or more boost beams with a non-tangential beam-direction were added con-
formal to the boost PTV. Beam weights, wedge fractions and MLC settings for all 
beams were manually adjusted in such a way that the 95%-isodose closely en-
compassed the PTVs in 3 dimensions, and volumes receiving P107% of the dose 
prescribed to the PTVs were minimized. No specific constraints for organs at risk 
were used. Beam directions, multileaf collimator settings, beam shapes and beam 
weights were manually optimised to minimise the dose to heart, lung and breast 
tissue as much as possible without compromising target coverage. Field in field 
segments were used to improve dose homogeneity and dose-to-target conformi-
ty. Attempts were made to cover at least 98% of virtual breast and boost PTVs 
(original PTVs excluding the build-up region) with 95% of the prescribed dose. All 
beams were delivered with a linear accelerator using 6 or 15 MV photons.
 Regional radiotherapy, including the axillary, supra and infraclavicular nodal areas, 
with or without the internal mammary nodes (IMN), was indicated in case of more 
than 3 axillary lymph node metastases or in case of a positive apical lymph node 
(total n = 45; 6%). Indications for IMN radiotherapy were medial located tumours 
with indication for regional radiotherapy, pathologic positive IMN sentinel node, and 
positive flow to an IMN lymph node, which was not removed during surgery.
Systemic therapy
Patients with node-positive disease and high risk node-negative tumours were 
treated with adjuvant systemic therapy according to national guidelines 3. Risk 
classification was based on tumour size, grade, hormonal receptor status and 
age. Chemotherapy consisted of 5-fluorouracil, epirubicin and cyclophosphamide 
(FEC) in 260 (97.7%) patients. Six patients received a combination of adriamycin 
and cyclophosphamide (AC). In this series, none of the patients was treated with 
taxane-based chemotherapy. In general, in node-positive disease, chemother-
apy was administered first followed by radiotherapy, whereas in node-negative 
patients, radiotherapy was given first. The treatment sequence was based on 
regional consensus of opinion. Adjuvant hormonal therapy was indicated for all 
intermediate and high risk hormonal receptor-positive patients.
 Depending on menopausal status, tamoxifen or aromatase inhibitors were giv-
en. For patients receiving chemotherapy, trastuzumab was recommended for all 
patients with tumours overexpressing the human epidermal growth factor recep-
tor 2 (HER2) 3.
Statistical analysis
Contingency tables were used to present the patient, tumour and treatment-re-
lated characteristics, number of first events and second cancers (i.e., malignancy 
not related to a recurrence or primary tumour). Furthermore, the observed pro-
portions of late toxicities are reported.
 The unadjusted 3-year actuarial rates of LC, locoregional control (LRC), RFP, 
and OS and corresponding 95% confidence intervals (CIs) were calculated using 
the Kaplan-Meier method. Given the median follow-up duration, we presented the 
3-year rates. The dataset was stratified according to age (≤ 50 and > 50 years) 






























Univariate analyses and multivariate analysis were performed using the Cox pro-
portional hazard model to identify prognostic factors for RFP. The covariates that 
were univariately related to the endpoint (p < 0.10) were entered in the multi-
variate analysis.
 Adjusted hazard ratios (HRs) and 95% CIs were calculated. In addition to the 
dichotomized covariate of age at diagnosis (≤ 50 and > 50 years), we explored 
the impact of other age groups in the analysis, by categorizing age in 4 subgroups 
(≤ 40, 41-50, 51-60 and > 60 years). Due to the high correlation between both 
oestrogen receptor status and triple negativity (i.e., oestrogen receptor (ER) neg-
ative, progesterone receptor (PR) negative, HER2 negative), and lymph node sta-
tus and regional radiotherapy (Pearson’s R > 0.8), only triple negative receptor 
status and lymph node status were included in the multivariate analysis.
 To explore the impact of competing risks on outcome, two sensitivity analyses 
were performed. First, all patients who developed a second cancer during fol-
low-up were excluded from the analysis and second, all patients who had a non 
breast cancer related death were excluded.
All tests were two-sided and probability values of < 0.05 were considered to be 
statistically significant. The analyses were performed using the SPPS software 
package, version 16.0 for Windows (SPSS, Chicago, IL, USA).
Results
Patterns of failure
Median follow-up was 41 (range 3-65) months. The patterns of failure are listed in 
Table 2. During follow-up, 6 patients developed an ipsilateral LR with a median time 
to LR of 33.5 (range 13-61) months, including 4 invasive tumours and 2 pure DCIS. 
Five out of these recurrences were in-breast recurrences and were treated with sal-
vage mastectomy. So far, these 5 patients 
remained disease-free. After 14 months of 
follow-up, 1 out of these 6 patients devel-
oped lymphangitis carcinomatosa in the 
treated breast with concurrent supracla-
vicular and distant metastases. She was 
treated with palliative chemotherapy, but 
died within 2 years.
 In the 2 patients with a pure DCIS LR, 
these were located outside the boost 
fields. In 2 other patients with an invasive 
LR, the LRs were localized just beneath 
the scar of the primary lumpectomy and 
within the boost PTV. The fifth invasive LR 
was seen in a patient with a multifocal pri-
mary tumour with extensive DCIS. The LR 
was present diffusely through the whole 
breast, with massive lymphangioinvasion.
 In total, 5 patients developed an isolated RR. In 2 patients, this RR was local-
ized in the axilla, in 1 patient in the supraclavicular region, in 1 patient in the IMN 
and in 1 patient in both supraclavicular and IMN simultaneously. None of these 
patients had been treated with regional radiotherapy and all RRs were located 
outside the primary radiation fields. Supraclavicular recurrences with concurrent 
distant metastases were observed in 2 patients. One of these 2 patients died of 
disease. During follow-up, 3 patients with a RR had disease progression with dis-
tant metastases. Two of these patients eventually died.
Distant metastases as first event developed in 27 patients, of whom 11 (40.7%) 
subsequently died. In total, 15 patients died of disease progression.
 Eleven patients died of other causes, including cerebrovascular events (n = 
2), liver cirrhosis (n = 1), suicide (n = 1), secondary malignancies (n = 5) and 
unknown causes (n = 2), respectively.
Primary outcomes
The 3-year LC was 99.6% (95% CI 99.5-99.6), RFP 95.5% (95% CI 95.4-95.5), 
and OS 97.1% (95% CI 97.0-97.1), respectively. In Figures 1 and 2, the Ka-
plan-Meier curves of LC and OS are shown. The actuarial 3-year rates, comparing 
young and old patients (≤ 50 and > 50 years at diagnosis) including the 95% CIs 
of all endpoints and the corresponding p-values of the log-rank test are listed in 
Table 3. No significant differences in clinical outcome were found according to age.
Secondary malignancies
Secondary malignancies developed in 28 patients (3.7%). In 11 cases, the sec-
ondary primary tumour was located in the contralateral breast. One patient 
(3.6%) developed oesophageal cancer; 7 other patients (25.0%) developed can-
cer elsewhere in the gastrointestinal tract; 3 patients (10.7%) lung cancer; 2 
patients (7.1%) head and neck cancer; 2 patients acute myeloid leukemia; 1 
patient ovarian cancer and 1 patient endometrial carcinoma. Five patients, who 
Local recurrence (LR) 1 6 (0.8)
Regional recurrence (RR) 2 8 (1.1)
Distant metastases (DM) 27 (3.6)
Death of disease 15 (2.0)
Death of all causes 26 (3.5)
Secondary malignancy 
 Contralateral breast cancer 11 (1.5)
 Ovarian cancer 1 (0.1)
 Other 16 (2.1)
First event n (%)
Table 2. Patterns of failure (n = 752)
Median time since diagnosis (mos) (range) 41 
(3-65).
1 One patient developed LR, RR and DM simulta- 
niously.
2 Two patients developed RR and DM simulta- 
niously.
Fig. 1. Kaplan-Meier curve of local control and ac-
uarial 3-year rate of included patients treated with 
breast-conserving surgery and 3D-CRT-SIB after inva-
sive breast cancer.
Fig. 2. Kaplan-Meier curve of overall survival and ac-
uarial 3-year rate of included patients treated with 































developed a second malignancy other than contralateral located breast cancer, 
died of this second cancer.
Late	toxicity
Toxicity scores were available in 612 patients (81.4%). The proportion of patients 
with grade 2 or higher fibrosis in the breast (i.e., fibrosis in the boost area and/or 
non-boost area) (n = 49), grade ≥ 2 telangiectasia in the treated breast (n = 19), 
breast oedema (n = 63), any pain to the thoracic wall (n = 42), and rib fractures 
(n = 2) were observed in 9.1%, 3.2%, 10.7%, 7.1%, and 0.4%, respectively. 
In total, 3 cases (0.5%) of pneumonitis grade 1 were reported. No fatal cardiac 
events were observed. One patient treated for right-sided breast cancer devel-
oped a myocardial infarction, while another patient treated for left-sided breast 
cancer was diagnosed with cardiac arrhythmia.
Univariate analysis
Because of the low number of events, univariate and multivariate analyses were only 
performed for RFP. In univariate analysis, significantly worse RFP was observed in 
patients with pathologic tumour size larger than 2 cm (HR 3.94, 95% CI 2.11-7.34, 
p < 0.001), patients with more than 3 positive lymph nodes (HR 3.22, 95% CI 1.22-
8.50, p = 0.018), grade III tumours (HR 2.90, 95% CI 1.56-5.41, p = 0.001), tu-
mours not expressing oestrogen receptor (HR 3.23, 95% CI 1.70-6.14, p < 0.001), 
tumours with triple negative receptor status (HR 4.02, 95% CI 2.06-7.84, p < 0.001) 
and those patients who received adjuvant chemotherapy (HR 2.14, 95% CI 1.15-
3.99, p = 0.02) or regional RT (HR 2.9, 95% CI 1.25-7.14, p = 0.01).
 Young age was no risk factor for RFP, neither among patients of ≤ 50 years (HR 
1.12, 95% CI 0.56-2.24, p = 0.76), nor among patients ≤ 40 years of age (HR 
0.63, 95% CI 0.20-1.91, p = 0.53).
Multivariate analysis
Tumour size and triple negative receptor status were the only two independent 
prognostic factors for RFP (Table 4). Patients with tumours larger than 2 cm had 
worse RFP than patients with tumours smaller than 2 cm. Furthermore, RFP was 
impaired in patients with triple negative receptor status compared to those with 
non-triple negative status.
 Excluding the secondary malignancies or non-breast cancer related deaths from 
the analysis did not change results and therefore both factors were not consid-
ered significant competing risks (data not shown).
Discussion
In this large consecutive series of patients treated with breast-conserving surgery 
and hypofractionated 3D-CRT-SIB irradiation, local control at 3 years was 99.6%, 
with only a few cases of grade 2 or higher late toxicity. The 3-year LRC and OS 
were 99.2% and 97.1%, respectively.
 In 2001, Bartelink et al. 13 pub-
lished the results of the random-
ized EORTC study 22881-10882, 
with one of the largest series treat-
ed with whole breast irradiation 
and a sequential boost of 16 Gy (n 
= 2,661). The radiotherapy boost 
was delivered in various ways (ex-
ternal beam electrons, photons or 
iridium-192 brachytherapy).
 Radiotherapy was generally 
not given with the use of modern 
3D CT-based radiotherapy tech-
niques. At 3 years of follow-up, LC 
and OS among patients who re-
ceived a boost dose in that study 
were 97.9% (95% CI 97.6-98.2) 
and 93.8% (95% CI not report-
ed), respectively. After publication 
of these results, whole breast ir-
radiation with a sequential boost 
of 16 Gy was introduced as stan-
dard of care in the Netherlands. 
The current 3D-CRT based study 
shows somewhat higher LC rates 
compared to the EORTC study by 
Bartelink et al.
 McDonald et al. recently reported on a series of 282 invasive breast cancer 
patients treated with Intensity-Modulated Radiation Therapy (IMRT)-SIB after 
breast-conserving surgery 14, and found 8 ipsilateral in-breast LR and 4 RR after a 
median follow-up of 33 months. The 3-year LRC and OS were 97.1% and 97.0% 
(95% CIs not reported), respectively. The characteristics of the study population 
were more or less comparable with that of the present series. Hence, the 99.6% 
LC rate in this consecutive series of breast cancer patients is promising and in 
line with the results found by others. Acute skin toxicity reported by others was 
also comparable to the toxicity we observed in the first 90 patients treated with 
3DCRT-SIB at our institution 6.
 Overall, our late toxicity rates seem to be acceptable; at 3 years, the inci-
dence of moderate to severe (i.e., grade ≥ 2) fibrosis in the breast was lower 
than the 20% observed in the EORTC study 22881-10882 5. Physician-rated late 
toxicity after the use of SIB-RT was reported in a small prospective non-ran-
domized study by Raiyawa et al. 15. In that study 60 patients were treated with 
whole breast irradiation (25 fractions of 2 Gy) combined with either a sequential 
electron boost of 5 fractions of 3 Gy (in total 15 Gy) or a SIB-electron boost of 
25 fractions of 0.4 Gy (10 Gy in total) to the tumour bed 15. At 7 months of fol-
Pathological T-stage 
 T1 1 
 T ≥ 2 3.11 (1.57-6.17) 0.0012 2
Pathological N-stage 
 N0 1 
 N1 1.19 (0.56-2.56) 0.65
 N2+ 2.18 (0.76-6.25) 0.15
Differentiation grade 
 I/II 1 
 III 1.52 (0.70-3.31) 0.29
Triple negative 3 
 No 1 
 Yes 3.03 (1.37-6.67) 0.006
Adjuvant chemotherapy 
 No 1 
 Yes 0.82 (0.38-1.77) 0.62
Characteristic HR (95% CI) p value
Table 4.  Multivariate model of recurrence-free period 1
Abbreviations:	HR	=	hazard	ratio;	CI	=	confidence	interval.
1 Adusted for all covariates in the model.
2	Bold	print	signifies	a	probability	value	<	0.05.
3 Oestrogen receptor negative, progesterone receptor nega- 






























low-up, grade ≥ 2 fibrosis was reported in 10% of patients, which is comparable 
to our results. No grade ≥ 2 telangiectasia, breast oedema, or rib fractures were 
observed. Most importantly, the toxicities were comparable between the two 
studied groups.
 Young age at diagnosis (≤ 50 years) was no risk factor for disease progres-
sion or any other endpoint considered in current series of breast cancer patients 
treated with BCT. In several other studies, young age was associated with worse 
clinical outcome, such as LC and survival after both BCT and mastectomy 7-10,13,16. 
The lack of impact of age on disease recurrence in our series could be explained 
by a number of factors. The small number of events in our series may have limit-
ed the ability to detect differences between groups, but could also indicate a safe 
selection of patients for BCT.
 Furthermore, the increased use of adjuvant systemic therapy, particularly in 
high risk node-negative patients might explain this lack of impact of age. In an 
overview of the randomized trials by the Early Breast Cancer Trialists’ Collabora-
tive Group (EBCTCG), both single agent and polychemotherapy have been shown 
to improve LC and survival significantly, with the largest gain in the youngest age 
groups (i.e., patients < 50 years) 17,18. Finally, another factor might be the boost 
dose, which was given to all patients. In our series, all patients received a boost, 
uniformly applied, which has been shown to further decrease the risk of local re-
currences 5.
 Another explanation for the lack of impact of age in our series might be the 
strong association between triple negative receptor status and disease progres-
sion. Triple negative receptor status resulted in a threefold increase of disease 
progression risk. Triple negative receptor status is strongly associated with poor 
clinical outcome 19,20. In general, young women have more frequently triple neg-
ative tumours 19,21. This could therefore be the biological explanation for worse 
outcome related to young age 7-10,13,16. The only study investigating the impact of 
age independently of triple negative status is a retrospective study of 375 breast 
cancer patients in which both triple negative disease and patients under 35 years 
of age were independent risk factors for any recurrence 22. This study by Kwon 
et al. was hampered by the fact that 31.5% of the patients did not receive any 
radiotherapy after breast-conserving surgery. Furthermore, it is not clear whether 
the other patients received a boost to the tumour bed. 
 Therefore, part of the local recurrences, especially in young women might be 
caused by inadequate local treatment. This could explain the relation found be-
tween age and recurrence.
 One disadvantage of our series is the relatively short follow-up with a median 
of 41 months. Although it is known that there is no plateau phase for in-breast 
recurrences, most true local recurrences develop in the first 3 to 4 years after 
treatment 23.
 Next to application of the SIB in 3D-CRT, the SIB can be used combined with 
IMRT (IMRT-SIB). A potential advantage of the IMRT-SIB over 3D-CRT-SIB is 
the possibility of reducing the dose in organs at risk (OARs), such as the heart, 
lungs and the contralateral breast. However, others showed that, in general, the 
same reductions of calculated dose to these OARs could be achieved in 3D-CRT-
SIB compared to IMRT-SIB 24-26. The combination of easy implementation of the 
3D-CRT-SIB without increasing the complexity and time involved with radiation 
treatment planning, the relatively mild acute skin toxicity 6 and the excellent 
results found in this series, justify the implementation of 3D-CRT-SIB as an alter-
native for breast-IMRT-SIB.
 In conclusion, 3D-CRT-SIB as part of BCT results in excellent local control, LRC 
and OS rates even in the younger population without excess in long term toxicity. 
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